We inform you about the current business development of HAEMATO AG and about our investor relations activities.
In consideration of the IFRS 15 "Revenues", which is mandatory from the financial year 2018, HAEMATO AG generated IFRS Group sales of EUR 274.1 million, an operating result (EBIT) of EUR 8.5 million and a net income of EUR 6.3 million. In the second half of 2018, as a...read more
HAEMATO AG was able to achieve an EBITDA of EUR 10.0m for the fiscal year 2018 according to preliminary IFRS financial statements. HAEMATO AG, Berlin (ISIN: DE0006190705), achieved consolidated sales of EUR 274.1m (previous year: EUR 289.4m), an operating...read more
In the third quarter of 2018 HAEMATO AG, Berlin (ISIN: DE0006190705), achieved IFRS consolidated sales of EUR 69.12 million (previous year: EUR 72.5 million). In the considered period of January till September 2018 the sales amounted to € 212.8 million...read more
In the first half of 2018, the HAEMATO Group increased sales by 3.6 % year-on-year to a total of EUR 143.7 million. EBIT amounted to kEUR 6,484.6 (prior year period: kEUR 3,182.8). The consolidated profit as of 30.06.2018 amounts to kEUR 5,044.5 and is therefore also...read more
HAEMATO AG announced today that the shareholders of the company have approved with a large majority all items on the agenda which were put to the vote by the administration at the Annual General Meeting on July 4, 2018 in Berlin. At the vote on agenda...read more
HAEMATO AG is a listed pharmaceutical company focusing on the growth markets of high-priced special pharmaceuticals from the indication areas oncology and HIV as well as in the areas of rheumatism, neurology and cardiovascular diseases. In addition, the...read more